In Salt Lake City on June 24, 2026, a company known as Sera Prognostics Inc., also referred to as The Pregnancy Company® and listed on Nasdaq as SERA, unveiled its commitment to enhancing maternal and neonatal health. By offering cutting-edge pregnancy biomarker data, the company aims to make a significant impact on the well-being of expecting mothers and their babies. This announcement coincides with their involvement in a collaborative research effort spanning multiple institutions.